A randomised, double-blind, placebo-controlled trial of dolasetron, a 5-hydroxytryptamine 3 receptor antagonist, in patients with fibromyalgia

Intermittent IV dolasetron was safe and efficacious for the reduction of pain intensity associated with FM at 3 months.